placebo

Those who received the injectable version achieved statistically significant weight loss of up to 14.5% compared with 2.6% in people treated with a placebo.

The company said Monday that the ingredient, called semaglutide, wasn’t superior to a placebo in reducing the progression of Alzheimer’s disease in the studies.

Participants on the highest dose of 36 milligrams lost around 10 percent of their body weight after 72 weeks, compared to two percent for the group taking a placebo, according to the study.

The analyses evaluated three GLP-1 receptor agonists used for weight management and found that each one produced clinically important weight loss when compared with placebo.

Half received colchicine, while the rest were given either a placebo or no added medication on top of their typical care.